- Home
- AKRO vs ATGE Comparison
AKRO vs ATGE Comparison
Compare AKRO & ATGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- ATGE
- Stock Information
- Founded
- AKRO 2017
- ATGE 1987
- Country
- AKRO United States
- ATGE United States
- Employees
- AKRO N/A
- ATGE N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- ATGE Other Consumer Services
- Sector
- AKRO Health Care
- ATGE Consumer Discretionary
- Exchange
- AKRO Nasdaq
- ATGE Nasdaq
- Market Cap
- AKRO 3.9B
- ATGE 4.1B
- IPO Year
- AKRO 2019
- ATGE 1991
- Fundamental
- Price
- AKRO $49.65
- ATGE $132.05
- Analyst Decision
- AKRO Strong Buy
- ATGE Strong Buy
- Analyst Count
- AKRO 8
- ATGE 3
- Target Price
- AKRO $82.50
- ATGE $135.67
- AVG Volume (30 Days)
- AKRO 1.9M
- ATGE 650.5K
- Earning Date
- AKRO 05-12-2025
- ATGE 05-08-2025
- Dividend Yield
- AKRO N/A
- ATGE N/A
- EPS Growth
- AKRO N/A
- ATGE 129.73
- EPS
- AKRO N/A
- ATGE 6.03
- Revenue
- AKRO N/A
- ATGE $1,741,091,000.00
- Revenue This Year
- AKRO N/A
- ATGE $13.72
- Revenue Next Year
- AKRO N/A
- ATGE $6.71
- P/E Ratio
- AKRO N/A
- ATGE $22.24
- Revenue Growth
- AKRO N/A
- ATGE 13.10
- 52 Week Low
- AKRO $17.86
- ATGE $62.28
- 52 Week High
- AKRO $58.40
- ATGE $140.12
- Technical
- Relative Strength Index (RSI)
- AKRO 63.34
- ATGE 62.97
- Support Level
- AKRO $44.94
- ATGE $125.96
- Resistance Level
- AKRO $49.29
- ATGE $132.95
- Average True Range (ATR)
- AKRO 3.33
- ATGE 4.20
- MACD
- AKRO 0.67
- ATGE -0.63
- Stochastic Oscillator
- AKRO 86.02
- ATGE 43.01
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.